The challenges of LC-MS/MS analysis of opiates and opioids in urine

Bioanalysis

Volumn 5, Issue 22, 2013, Pages 2803-2820

  French, Deborah ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 ETHYLIDENE 1,5 DIMETHYL 3,3 DIPHENYLPYRROLIDINE; BUPRENORPHINE; BUPRENORPHINE 3 GLUCURONIDE; BUPRENORPHINE PLUS NALOXONE; CODEINE; DIAMORPHINE; DIHYDROCODEINE; DIHYDROMORPHINE; ENDORPHIN; FENTANYL; HYDROCODONE; HYDROMORPHONE; METHADONE; MORPHINE; MORPHINE 6 ACETATE; NALOXONE; NALOXONE 3 GLUCURONIDE; NARCOTIC ANALGESIC AGENT; NORBUPRENORPHINE; NORBUPRENORPHINE 3 GLUCURONIDE; NORCODEINE; NORFENTANYL; NOROXYCODONE; NOROXYMORPHONE; OPIATE; OXYCODONE; OXYMORPHONE; OXYMORPHONE 3 GLUCURONIDE; PETHIDINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANALGESIA; ANESTHESIA; DILUTION; DRUG DETERMINATION; DRUG HYDROLYSIS; DRUG METABOLISM; DRUG SCREENING; HUMAN; LIQUID CHROMATOGRAPHY; NONHUMAN; ONLINE ANALYSIS; OPIATE ADDICTION; PAIN; PRECIPITATION; QUANTITATIVE ANALYSIS; RESPIRATION DEPRESSION; REVIEW; SOLID PHASE EXTRACTION; TANDEM MASS SPECTROMETRY; TOXICITY TESTING; URINALYSIS;

ANALGESICS; ANALGESICS, OPIOID; ANIMALS; CHROMATOGRAPHY, LIQUID; HUMANS; TANDEM MASS SPECTROMETRY;

EID: 84889569083     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.13.244     Document Type: Review

References (79)

1. Matthes HW, Maldonado R, Simonin F et al. Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the μ-opioid receptor gene. Nature 383, 819-823 (1996
2. Fricchione GL, Mendoza A, Stefano GB. Morphine and its psychiatric implications. Adv. Neuroimmunol. 4(2), 117-131 (1994 (Pubitemid 24238993)
3. Pattinson KT. Opioids and the control of respiration. Br. J. Anaesth. 100(6), 747-758 (2008 (Pubitemid 351774332)
4. Manara L, Bianchi G, Ferretti P, Tavani A. Inhibition of gastrointestinal transit by morphine in rats results from direct drug action on gut opioid sites. J. Pharmacol. Exp. Ther. 237(3), 945-949 (1986 (Pubitemid 16088118)
5. Feng Y, He X, Yang Y, Chao D, Lazarus LH, Xia Y. Current research on opioid receptor function. Curr. Drug Targets 13(2), 230-246 (2012
6. Boyer EW. Management of opioid analgesic overdose. N. Engl. J. Med. 367(2), 146-155 (2012
7. Manchikanti L, Helm S 2nd, Fellows B et al. Opioid epidemic in the United States. Pain Physician 15, ES9-ES38 (2012
8. Manchikanti L, Singh A. Therapeutic opioids: A ten-year perspective on the complexities and complications of the escalating use, abuse and non-medical use of opioids. Pain Physician 11, S63-S88 (2008 (Pubitemid 351682079)
9. Bronstein AC, Spyker DA, Cantilena LR Jr, Rumack BH, Dart RC. 2011 annual report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 29th annual report. Clin. Toxicol. Phila) 50(10), 911-1164 (2012
10. Cunha-Oliveira T, Rego AC, Oliveira CR. Cellular and molecular mechanisms involved in the neurotoxicity of opioid and psychostimulant drugs. Brain Res. Rev. 58, 192-208 (2008
11. Karow A, Verthein U, Krausz M, Schäfer I. Association of personality disorders, family conflicts and treatment with quality of life in opiate addiction. Eur. Addict. Res. 14, 38-46 (2008
12. Ivanov IS, Schulz, KP, Palmero RC, Newcorn JH. Neurobiology and evidence-based biological treatments for substance abuse disorders. CNS Spectr. 11(11), 864-877 (2006 (Pubitemid 44845664)
13. Birnbaum HG, White AG, Reynolds JL et al. Estimated costs of prescription opioid analgesic abuse in the United States in 2001. A societal perspective. Clin. J. Pain 22, 667-676 (2006 (Pubitemid 44434948)
14. Rook EJ, Huitema ADR, van den Brink W, van Ree JM, Beijnen JH. Pharmacokinetics and pharmacokinetic variability of heroin and its metabolites: Review of the literature. Curr. Clin. Pharmacol. 1(1), 109-118 (2006
15. Baselt RC. Disposition of Toxic Drugs and Chemicals in Man. (7th Edition). Biomedical Publications, Foster City, CA, USA (2004
16. Milne RW, Nation RL, Somogyi AA. The disposition of morphine and its 3- and 6-glucuronide metabolites in humans and animals, and the importance of the metabolites to the pharmacological effects of morphine. Drug Metab. Rev. 28(3), 345-472 (1996 (Pubitemid 26300413)
17. Coffman BL, Rios GR, King CD, Tephly TR. Human UGT2B7 catalyzes morphine glucuronidation. Drug Metab. Dispos. 25(1), 1-4 (1997 (Pubitemid 27045126)
18. Coffman BL, King CD, Rios GR, Tephly TR. The glucuronidation of opioids, other xenobiotics, and androgens by human UGT2B7Y(268) and UGT2B7H(268). Drug Metab. Dispos. 26(1), 73-77 (1998 (Pubitemid 28071328)
19. Paul D, Standifer KM, Inturrisi CE, Pasternak GW. Pharmacological characterization of morphine-6-beta-glucuronide, a very potent morphine metabolite. J. Pharmacol. Exp. Ther. 251(2), 477-483 (1989 (Pubitemid 20005587)
20. Yeh SY, Gorodetzky CW, Krebs HA. Isolation and identification of morphine 3- and 6-glucuronides, morphine-3,6-diglucuronide, morphine 3-ethereal sulfate, normorphine, and normorphine 6-glucuronide as morphine metabolites in humans. J. Pharm. Sci. 66(9), 1288-1293 (1977 (Pubitemid 8163981)
21. Projean D, Morin P-E, Tu TM, Ducharme J. Identification of CYP3A4 and CYP2C8 as the major cytochrome P450s responsible for morphine N-demethylation in human liver microsomes. Xenobiotica 33(8), 841-854 (2003 (Pubitemid 37129907)
22. Mannering GJ, Dixon AC, Baker EM 3rd, Asami T. The in vivo liberation of morphine from codeine in man. J. Pharmacol. Exp. Ther. 111(2), 142-146 (1954
23. Nomof N, Elliott HW, Parker KD. Actions and metabolism of codeine (methylmorphine) administration by continuous intravenous infusion to humans. Clin. Toxicol. 11(5), 517-529 (1977 (Pubitemid 8305643)
24. Srinivasan V, Wielbo D, Simpkins J, Karlix J, Sloan K, Tebbett I. Analgesic and immunomodulatory effects of codeine and codeine 6-glucuronide. Pharm. Res. 13(2), 296-300 (1996 (Pubitemid 26072151)
25. Cone EJ, Darwin WD, Gorodetzky CW. Comparative metabolism of codeine in man, rat, dog, guinea-pig and rabbit: Identification of four new metabolites. J. Pharm. Pharmacol. 31, 314-317 (1979 (Pubitemid 9207596)
26. Cone EJ, Heit HA, Yale HC, Gourlay D. Evidence of morphine metabolism to hydromorphone in pain patients chronically treated with morphine. J. Anal. Toxicol. 30(1), 1-6 (2006
27. Oyler JM, Cone EJ, Hoseph RE Jr, Huestis MA. Identification of hydrocodone in human urine following controlled codeine administration. J. Anal. Toxicol. 24(7), 530-535 (2000
28. Cone EJ, Darwin WD, Gorodetzky CW, Tan T. Comparative metabolism of hydrocodone in man, rat, guinea pig, rabbit and dog. Drug Metab. Dispos. 6(4), 488-493 (1978 (Pubitemid 8399700)
29. Otton SV, Schadel M, Cheung SW, Kaplan HI, Busto UE, Sellers EM. CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone. Clin. Pharmacol. Ther. 54(5), 463-472 (1993 (Pubitemid 23349082)
30. Valtier S, Bebarta VS. Excretion profile of hydrocodone, hydromorphone and norhydrocodone in urine following single dose administration of hydrocodone to healthy volunteers. J. Anal. Toxicol. 36(7), 507-514 (2012
31. Baselt RC, Stewart CB. Determination of oxycodone and a major metabolite in urine by electron-capture GLC. J. Anal. Toxicol. 2(3), 107-109 (1978 (Pubitemid 8384715)
32. Lalovic B, Kharasch E, Hoffer C, Risler L, Liu-Chen L-Y, Shen DD. Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: Role of circulating active metabolites. Clin. Pharmacol. Ther. 79(5), 461-479 (2006
33. Cone EJ, Heltsley R, Black DL, Mitchell JM, LoDico CP, Flegel RR. Prescription opioids. I. Metabolism and excretion patterns of oxycodone in urine following controlled single dose administration. J. Anal. Toxicol. 37(5), 255-264 (2013
34. Cone EJ, Darwin WD, Buchwald WF, Gorodetzky CW. Oxymorphone metabolism and urinary excretion in human, rat, guinea-pig, rabbit, and dog. Drug Metab. Dispos. 11(5), 446-450 (1983 (Pubitemid 13021124)
35. Labroo RB, Paine MF, Thummel KE, Kharasch ED. Fentanyl metabolism by human hepatic and intestinal cytochrome P450 3A4: Implications for interindividual variability in disposition, efficacy and drug interactions. Drug Metab. Dispos. 25(9), 1072-1080 (1997 (Pubitemid 27396495)
36. Moody DE. Metabolic and toxicological considerations of the opioid replacement therapy and analgesic drugs: Methadone and buprenorphine. Expert Opin. Drug Metab. Toxicol. 9(6), 675-697 (2013
37. Yang A, Arfken CL, Johanson C-E. Steps physicians report taking to reduce diversion of buprenorphine. Am. J. Addict. 22(3), 184-187 (2013
38. Marsch LA, Stephens MAC, Mudric T, Strain EC, Bigelow GE, Johnson RE. Predictors of outcome in LAAM, buprenorphine and methadone treatment for opioid dependence. Exp. Clin. Psychopharmacol. 13(4), 293-302 (2005 (Pubitemid 43011154)
39. Manchikanti L, Manchukonda R, Pampati V et al Does random urine drug testing reduce illicit drug use in chronic pain patients receiving opioids? Pain Physician 9(2), 123-129 (2006
40. Katz N, Fanciullo GJ. Role of urine toxicology testing in the management of chronic opioid therapy. Clin. J. Pain 18(4 Suppl.), S76-S82 (2002 (Pubitemid 34815397)
41. Reisfield GM, Salazar E, Bertholf RL. Rational use and interpretation of urine drug testing in chronic opioid therapy. Ann. Clin. Lab. Sci. 37(4), 301-314 (2007 (Pubitemid 350105930)
42. Reisfield GM, Goldberger BA, Bertholf RL. 'False-positive' and 'false-negative' test results in clinical urine drug testing. Bioanalysis 1(5), 937-952 (2009
43. Wu AHB, McKay C, Broussard LA et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Recommendations for the use of laboratory tests to support poisoned patients who present to the emergency department. Clin. Chem. 49(3), 357-379 (2003 (Pubitemid 36250197)
44. Villena VP. Beating the system: A study of a creatinine assay and its efficacy in authenticating human urine specimens. J. Anal. Toxicol. 34(1), 39-44 (2010
45. Cook JD, Caplan YH, LoDico CP, Bush DM. The characterization of human urine for specimen validity determination in workplace drug testing: A review. J. Anal. Toxicol. 24(7), 579-588 (2000
46. Fox EJ, Twigger S, Allen KR. Criteria for opiate identification using liquid chromatography linked to tandem mass spectrometry: Problems in routine practice. Ann. Clin. Biochem. 46(Pt 1), 50-57 (2009
47. French D, Wu AHB, Lynch K. Hydrophilic interaction LC-MS/MS analysis of opioids in urine: Significance of glucuronide metabolites. Bioanalysis 3(23), 2603-2612 (2011
48. Dickerson JA, Laha TJ, Pagano MB, O'Donnell BR, Hoofnagle AN. Improved detection of opioid use in chronic pain patients through monitoring of opioid glucuronides in urine. J. Anal. Toxicol. 36(8), 541-547 (2012
49. Annesley TM. Ion suppression in mass spectrometry. Clin. Chem. 49(7), 1041-1044 (2003 (Pubitemid 36751088)
50. Matuszewski BK, Constanzer ML, Chavez-Eng CM. Strategies for the assessment of matrix effect matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Anal. Chem. 75(13), 3019-3030 (2003 (Pubitemid 36830428)
51. Dams R, Huestis MA, Lambert WE, Murphy CM. Matrix effect in bioanalysis of illicit drugs with LC-MS/MS: Influence of ionization type, sample preparation and biofluid. J. Am. Soc. Mass Spectrom. 14(11), 1290-1294 (2003 (Pubitemid 37330133)
52. Goldberger BA, Cone EJ. Confirmatory tests for drugs in the workplace by gas chromatography-mass spectrometry. J. Chromatogr. A 674(1-2), 73-86 (1994 (Pubitemid 24244769)
53. Marquet P, Lachâtre G. Liquid chromatography-mass spectrometry: Potential in forensic and clinical toxicology. J. Chromatogr. B Biomed. Sci. Appl. 733(1-2), 93-118 (1999
54. Heltsley R, Zichterman A, Black DL et al. Urine drug testing of chronic pain patients. II. Prevalence patterns of prescription opiates and metabolites. J. Anal. Toxicol. 34, 32-38 (2010
55. Cone EJ, Zichterman A, Heltsley R et al. Urine testing for norcodeine, norhydrodone, and noroxycodone facilitates interpretation and reduces false negatives. Forensic Sci. Int. 198(1), 58-61 (2010
56. Concheiro M, Castro AD, Quintela O, Cruz A, López-Rivadulla M. Determination of illicit drugs and their metabolites in human urine by liquid chromatography tandem mass spectrometry including relative ion intensity criteria. J. Anal. Toxicol. 31(9), 573-580 (2007 (Pubitemid 350291669)
57. Fitzgerald RL, Griffin TL, Yun Y-M et al. Dilute and shoot: Analysis of drugs of abuse using selected reaction monitoring for quantification and full scan product ion spectra for identification. J. Anal. Toxicol. 36, 106-111 (2012
58. Dams R, Murphy CM, Lambert WE, Huestis MA. Urine drug testing for opioids, cocaine and metabolites by direct injection liquid chromatography/ tandem mass spectrometry. Rapid Commun. Mass Spectrom. 17(14), 1665-1670 (2003 (Pubitemid 36841349)
59. Shakleya DM, Dams R, Choo RE, Jones H, Huestis MA. Simultaneous liquid chromatography-mass spectrometry quantification of urinary opiates, cocaine, and metabolites in opiate-dependent pregnant women in methadone-maintenance treatment. J. Anal. Toxicol. 34(1), 17-25 (2010
60. Dowling G, Regan L, Tierney J, Nangle M. A hybrid liquid chromatography-mass spectrometry strategy in a forensic laboratory for opioid, cocaine and amphetamine classes in human urine using a hybrid linear ion trap-Triple quadrupole mass spectrometer. J. Chromatogr. A 1217(44), 6857-6866 (2010
61. Edinboro LE, Backer RC, Poklis A. Direct ana¬lysis of opiates in urine by liquid chromatography-Tandem mass spectrometry. J. Anal. Toxicol. 29(7), 704-710 (2005 (Pubitemid 41803361)
62. Thörngren J-O, Östervall F, Garle M. A high-Throughput multicomponent screening method for diuretics, masking agents, central nervous system (CNS) stimulants and opiates in human urine by UPLC-MS/MS. J. Mass Spectrom. 43(7), 980-992 (2008 (Pubitemid 352029667)
63. Gustavsson E, Andersson M, Stephanson N, Beck O. Validation of direct injection electrospray LC-MS/MS for confirmation of opiates in urine drug testing. J. Mass Spectrom. 42(7), 881-889 (2007 (Pubitemid 47057070)
64. Bonfiglio R, King RC, Olah TV, Merkle K. The effects of sample preparation methods on the variability of the electrospray ionization response for model drug compounds. Rapid Commun. Mass Spectrom. 13(12), 1175-1185 (1999 (Pubitemid 29285118)
65. Murphy CM, Huestis MA. LC-ESI-MS/MS ana¬lysis for the quantification of morphine, codeine, morphine-3-b-d-glucuronide, morphine-6-b-d-glucuronide, and codeine-6-b-d-glucuronide in human urine. J. Mass Spectrom. 40, 1412-1416 (2005 (Pubitemid 41667204)
66. Coles R, Kushnir MM, Nelson GJ, McMillin GA, Urry FM. Simultaneous determination of codeine, morphine, hydrocodone, hydromorphone, oxycodone and 6-Acetylmorphine in urine, serum, plasma, whole blood, and meconium by LC-MS-MS. J. Anal. Toxicol. 31(1), 1-10 (2007
67. Berg T, Lundanes E, Christophersen AS, Stand DH. Determination of opiates and cocaine in urine by high pH mobile phase reversed phase UPLC-MS/MS. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 877(4), 421-432 (2009
68. McMillin GA, Davis R, Carlisle H, Clark C, Marin SJ, Moody DE. Patterns of free (unconjugated) buprenorphine, norbuprenorphine and their glucuronides in urine using liquid chromatography-Tandem mass spectrometry. J. Anal. Toxicol. 36(2), 81-87 (2012
69. Musshoff F, Trafkowski J, Kuepper U, Madea B. An automated and fully validated LC-MS/MS procedure for the simultaneous determination of 11 opioids used in palliative care, with 5 of their metabolites. J. Mass Spectrom. 41(5), 633-640 (2006 (Pubitemid 44023118)
70. Maralikova B, Weinmann W. Confirmatory analysis for drugs of abuse in plasma and urine by high-performance liquid chromatography-Tandem mass spectrometry with respect to criteria for compound identification. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 811(1), 21-30 (2004 (Pubitemid 39348844)
71. de Jager AD, Bailey NL. Online extraction LC-MS/MS method for simultaneous quantitative confirmation of urine drugs of abuse and metabolites: Amphetamines, opiates, cocaine, cannabis, benzodiazepines and methadone. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 879(29), 2642-2652 (2011
72. Liu A-C, Lin T-Y, Su L-W, Fuh M-R. Online solid-phase extraction liquid chromatography-electrospray-Tandem mass spectrometry analysis of buprenorphine and three metabolites in human urine. Talanta 75(1), 198-204 (2008
73. Schaefer N, Peters B, Schmidt P, Ewald AH. Development and validation of twoLC-MS/MS methods for the detection and quantification of amphetamines, designer amphetamines, benzoylecgonine, benzodiazepines, opiates, and opioids in urine using turbulent flow chromatography. Anal. Bioanal. Chem. 405(1), 247-258 (2013
74. Hemström P, Irqum K. Hydrophilic interaction chromatography. J. Sep. Sci. 29(12), 1784-1821 (2006 (Pubitemid 44348484)
75. Brown PR, Krstulovic AM. Practical aspects of reversed-phase liquid chromatography applied to biochemical and biomedical research. Anal. Biochem. 99(1), 1-21 (1979 (Pubitemid 10197701)
76. Jian W, Edom RW, Xu Y, Weng N. Recent advances in application of hydrophilic interaction chromatography for quantitative analysis. J. Sep. Sci. 33, 681-697 (2010
77. Jian W, Xu Y, Edom RW, Weng N. Analysis of polar metabolites by hydrophilic interaction chromatography-MS/MS. Bioanalysis 3(8), 899-912 (2011
78. Cone EJ, Gorodetzky CW, Yousefnejad D, Buchwald WF, Johnson RE. The metabolism and excretion of buprenorphine in humans. Drug Metab. Dispos. 12(5), 577-581 (1984 (Pubitemid 14020828)
79. Huang M-Z, Yuan C-H, Cheng S-C, Cho Y-T, Shiea J. Ambient ionization mass spectrometry. Annu. Rev. Anal. Chem. 3, 43-65 (2010